Last reviewed · How we verify
Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.
Details
| Lead sponsor | University Hospital Carl Gustav Carus |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 9 |
| Start date | 2002-03 |
| Completion | 2004-03 |
Conditions
- Multiple Myeloma
- Plasmocytoma
Interventions
- autologous idiotype-protein pulsed dendritic cells
Primary outcomes
- Specific T-cell proliferation/cytokine secretion
Countries
Germany